Compare FedEx Corporation (FDX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Novartis AG — how do they compare? FedEx Corporation trades at $292.3 (market cap $68.41B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 4× FedEx Corporation's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Novartis AG for 82 Days on average.
| FDX | NVS | |
|---|---|---|
Market Cap | $68.41B | $274.00B |
Volume | 1,232,551 | 1,852,137 |
Sector | Industrials | Health |
52-Week High | $339.35 | $168.62 |
52-Week Low | $180.87 | $121.80 |
Typical Hold Time | 87 Days | 82 Days |
Enterprise Value | $98.04B | $315.32B |
Dividend Yield | 1.69% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.73, up 0.93% today, with a bearish technical signal from moving averages and oscillators. The company shows solid fundamentals with a P/E of 15.58 and net income margin of 4.68%, though revenue has been flat near $88B. Recent news includes a $300M electric truck order and shareholder approval of executive pay, while earnings have beaten estimates in recent quarters.
The outlook is mixed: analyst consensus is bullish with a $307.55 price target, but rising fuel costs and net cash outflows pose risks. Investment appeal lies in cost-cutting efforts and industry recovery, balanced against macroeconomic pressures and competitive threats in logistics.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
